Please assess the completion status of the following clinical trial:

Trial Title: CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Male and female patients, aged 18 and above.~* ApoA-I \< 70 mg/dL~* Symptomatic or asymptomatic cardiovascular disease~* Diagnosis of genetically confirmed HDL-c deficiency due to defects in genes coding for ABCA1 and/or ApoA-1~* Stable doses of lipid lowering therapies for at least 6 weeks prior to baseline procedures~Main Exclusion Criteria:~* Females of childbearing potential~* Patients with LCAT mutations~* Patients who experienced recent cardiovascular or cerebrovascular events~* Hypertriglyceridemia (\>500 mg/dL)~* Severe anemia (Hgb \< 10 g/dL)~* Uncontrolled diabetes (HbA1c \>10%)~* Congestive heart failure (NYHA class II or higher)~* Contraindication for MRI scanning (e.g., implanted metal objects, claustrophobia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CER-001 (Type: EXPERIMENTAL): CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
- Placebo (Type: PLACEBO_COMPARATOR): Saline infusion; 9 weekly infusions followed by 20 biweekly infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).